Source: Annual Congress 2006 - Pulmonary hypertension: diagnostic tools and therapeutic approaches
Disease area: Pulmonary vascular diseases



Rating:

Share or cite this content

Citations should be made in the following way:
B. P. Madden, T. K. Loke, M. Allenby, A. Sheth (London, United Kingdom). A potential role for sildenafil in the management of pulmonary hypertension associated with parenchymal lung disease. Eur Respir J 2006; 28: Suppl. 50, 2487

Member's Comments

No comment yet.

Related content which might interest you: Bosentan for sarcoidosis associated pulmonary arterial hypertension (BoSAPH) was effective in advanced parenchymal lung disease Source: Annual Congress 2012 - Sarcoidosis Year: 2012 The effect of lung diseases on pulmonary hypertension and the effect of pulmonary hypertension on the lung Source: Virtual Congress 2021 – Pulmonary hypertension in the COVID-19 pandemic and beyond Year: 2021 Biomarkers in pulmonary hypertension associated to interstitial lung disease Source: Annual Congress 2010 - Pulmonary circulation II Year: 2010 Clinical characteristics, haemodynamics, and survival in patients with combined pulmonary fibrosis and emphysema and associated pulmonary hypertension Source: Annual Congress 2008 - Pulmonary vascular medicine Year: 2008 Can ADMA play a role in determining pulmonary hypertension related to chronic obstructive lung disease? Source: International Congress 2016 – Pulmonary hypertension in lung disease Year: 2016 Mild parenchymal lung disease and/or low diffusion capacity impacts survival and treatment response in patients diagnosed with idiopathic pulmonary arterial hypertension Source: Virtual Congress 2020 – Pulmonary hypertension in lung diseases Year: 2020 Mild parenchymal lung disease and/or low diffusion capacity impacts survival and treatment response in patients diagnosed with idiopathic pulmonary arterial hypertension Source: Eur Respir J, 55 (6) 2000041; 10.1183/13993003.00041-2020 Year: 2020 The change of lung diffusion capacity does not influence the prognosis in patients with pulmonary arterial hypertension associated with systemic sclerosis. Source: International Congress 2019 – Endpoints and risk assessment of pulmonary arterial hypertension Year: 2019 Pulmonary vascular resistance predicts mortality in patients with pulmonary hypertension associated with interstitial lung disease: results from the COMPERA registry Source: Eur Respir J, 58 (2) 2101483; 10.1183/13993003.01483-2021 Year: 2021 Is sildenafil an effective bridging therapy to lung transplantation for patients with pulmonary hypertension in the setting of lung disease? Source: International Congress 2015 – Pulmonary hypertension in lung disease Year: 2015 Determination of pulmonary hypertension degree in patients with interstitial lung diseases Source: Annual Congress 2010 - Different patterns of interstitial lung disease Year: 2010 Sildenafil is a potent pulmonary vasodilator in pulmonary hypertension associated with interstitial lung disease: impact on gas exchange properties Source: Eur Respir J 2002; 20: Suppl. 38, 598s Year: 2002 Is inflammation a potential therapeutic target in chronic thromboembolic pulmonary hypertension? Source: Eur Respir J 2014; 44: 842-845 Year: 2014 Acute exacerbations and pulmonary hypertension in advanced idiopathic pulmonary fibrosis Source: Eur Respir J 2012; 40: 93-100 Year: 2012 Risk assessment in severe pulmonary hypertension due to interstitial lung disease Source: Virtual Congress 2020 – Pulmonary hypertension in lung diseases Year: 2020 Pulmonary hypertension in patients with interstitial lung disease Source: Annual Congress 2011 - Clinical perspectives in several interstitial diseases Year: 2011 Pulmonary function measures predict mortality differently in IPF versus combined pulmonary fibrosis and emphysema Source: Eur Respir J 2011; 37: 176-183 Year: 2011 Novel treatment for pulmonary vascular disease: lessons from pathophysiology Source: Annual Congress 2006 - Molecular pathology: an approach to lung diseases Year: 2006 Treatment of pulmonary hypertension in chronic obstructive pulmonary disease Source: ISSN=ISSN 1025-448x, ISBN=ISBN 1-904097-48-0, page=313 Year: 2006